Study Results from Ningbo University in the Area of Liver Cancer Reported [Roles of Clinical Application of Lenvatinib and Its Resistance Mechanism In Advanced Hepatocellular Carcinoma (Review)].

A study conducted at Ningbo University in Zhejiang, People's Republic of China, focused on the roles of Lenvatinib in treating advanced hepatocellular carcinoma (HCC) and its resistance mechanisms. The research highlighted the dysregulation of crucial signaling pathways, noncoding RNA, and RNA modifications associated with Lenvatinib resistance. The study also discussed the potential of combination therapy to enhance the efficacy of Lenvatinib in treating advanced HCC. This peer-reviewed research provides new insights into Lenvatinib resistance and treatment strategies for advanced liver cancer. [Extracted from the article]